Jiangbo Pharmaceuticals (ehem. GNPH) - A0RNJB/JGBO
http://finance.yahoo.com/q/bs?s=JGBO+Balance+Sheet&annual
An der otc lag der Kurs höher.
Das Uplisting ist in keinster Weise angekommen,das ist wirklich ein Witz.
Immer dran denken,jiangbo ist keine otc-Klitsche
http://www.fixyou.co.uk/screens.php
Dazu der Link
Dort unter balance sheet zu lesen
http://finance.yahoo.com/q/ks?s=JGBO+Key+Statistics
http://finance.yahoo.com/news/...s-prnews-522392047.html?x=0&.v=1
Dei Firma liefert durch ihren Ausblick auch keinen Grund dazu.
Viel interressanter weden einige Informationen aus dem Quartalsbericht sein.
Was ist mit den warrents und den zu zahlenden Zinsen,die nicht wie gefordert in USD beglichen werden können?
Was wird auf dem erworbenen Grundstück geplant,es ist nicht klein.
Was wird mit dem ganzen Cash gemacht,zumindest sollte man ein paar neue meds damit erwerben.
Im Gespräch war immer ein neues Klasse1 med,wo bleib es ?
Vorallendigen,was ist mit hongrui?
Die Produktion sollte schon längst laufen...
Based on current information, the Company expects that revenues for fiscal year 2011 will be in the range of $94 million and $96 million and net income, excluding the impact from change in fair value of derivative liabilities and expenses related to the Company's convertible debentures, will be in the range of $29 million and $31 million.
Da hongrui noch nicht läuft,dividier ich mal 94:4 macht 23,5mill,zieh davon 3 mill für hongrui ab.Da bleiben nur ca.20-21mill übrig.
Ich lass mich sehr gerne positiv überraschen.
http://www.dailyfinance.com/company/...0-Q/101192925/html/sec-filings
SALES NET INCOME
§
$
§
27,670 10,574,688
16.11.2010 15:02
Jiangbo Pharmaceuticals Announces First Quarter Fiscal Year 2011 Results
LAIYANG, China, Nov. 16, 2010 /PRNewswire-Asia-FirstCall/ -- Jiangbo Pharmaceuticals, Inc. ("Jiangbo" or the "Company"), a pharmaceutical company with its principal operations in the People's Republic of China, today announced financial results for its first quarter ended September 30, 2010.
First Quarter Fiscal Year 2011 Highlights: -- Revenues increased 13.5% year-over-year to $27.7 million -- Gross profit was $20.0 million, up 10.4% from the comparable period in fiscal 2010 -- Operating income increased 14.8% year-over-year to $14.6 million -- Net income increased 436.3% to $10.6 million, or $0.29 per fully diluted share -- Non-GAAP adjusted net income was $10.1 million, or $0.67 per fully diluted share, for the three months ended September 30, 2010, up 14.0% from non-GAAP adjusted net income of $8.9 million, or $0.60 per fully diluted share, for the quarter ended September 30, 2009 -- Jiangbo started the production and sale of Felodipine sustained release tablets -- Cash and equivalents as of September 30, 2010 totaled $123.9 million
"We are pleased with this quarter's year-over-year revenue growth, which was driven by increased sales of our top three products, Clarithromycin, Itopride Hydrochloride, and Radix Isatidis dispersible tablets," said Mr. Linxian Jin, Jiangbo's Chief Executive Officer. "We also are excited about the early performance of our Felodipine sustained release tablets, which we officially launched during the first quarter. We believe that this new drug, along with the anticipated production of several traditional Chinese medicines at our Hongrui facility, will begin to contribute meaningfully to revenue as we head into 2011."
First Quarter Fiscal Year 2011 Results
Total revenue increased 13.5% year-over-year to $27.7 million from $24.4 million. The Company generated revenue from six drugs during the quarter ended September 30, 2010, with Clarithromycin sustained release tablets accounting for 42.6% of total sales, Itopride Hydrochloride granules 24.0%, Radix Isatidis dispersible tablets 15.7%, Baobaole chewable tablets 15.7% and Felodipine sustained release tablets and Paracetamol tablets accounting for 2.0% in total sales during the quarter. The overall increase in revenue for the three months ended September 30, 2010, as compared to the year ago quarter, was primarily attributable to increased sales volumes of Clarithromycin, Itopride and Radix Isatidis, which was partially offset by a decrease in sales generated from Baobaole chewable tablets.
Gross profit increased 10.4% to $20.0 million, from $18.1 million in the comparable period of fiscal year 2010. Gross margin decreased to 72.3% from 74.3% in the year ago quarter, mainly reflecting higher raw material costs for Radix Isatidis.
Selling, general and administrative expenses increased 3.3% to $4.5 million from $4.3 million in the same period of fiscal year 2010, primarily due to higher marketing and promotional expenditures in an effort to boost sales in fiscal year 2011.
Operating income increased 14.8% to $14.6 million, as compared to $12.7 million in the same period of fiscal year 2010. Operating margin as a percentage of revenue increased to 52.6% from 52.0% in the same period of fiscal year 2010.
Other expenses, comprised primarily of financial expenses, change in fair value of derivative liabilities and other non-operating expenses (income), were $0.2 million for the three months ended September 30, 2010, as compared to $7.4 million for the three months ended September 30, 2009. The decrease in other expenses in fiscal first quarter 2011 was primarily due to a $7.5 million gain in change in fair value of derivative liabilities, compared to a corresponding $4.8 million loss in the same period in fiscal 2009, partially offset by a $4.7 million increase in the debt discount amortization expense and financing interest and penalty expenses related to the Company's financings in November 2007 and May 2008.
The provision for income taxes was $3.8 million in the first quarter of fiscal year 2010, compared to $3.3 million for the three months ended September 30, 2009.
Net income increased 436.3% to $10.6 million, or $0.29 per diluted share, from $2.0 million in the prior year's comparable period.
Excluding the impact of an unrealized gain on investments of $2,874, a gain in fair value of derivative liabilities of $7.5 million, and amortization of debt discount and issuance costs related to convertible debentures of $7.0 million, non-GAAP adjusted net income for the first quarter of fiscal year 2011 was $10.1 million, or $0.83 per basic share, as compared to $8.9 million, or $0.85 per basic share, in the first quarter of fiscal year 2010. Non GAAP adjusted fully diluted earnings per share were $0.67, as compared to $0.60 in the first quarter of fiscal year 2010. (For a reconciliation of adjusted non-GAAP net income and basic and diluted earnings per share with their nearest GAAP equivalents, please see the table at the end of this press release.)
Financial Condition
As of September 30, 2010, the Company had $123.9 million in cash, as compared to $108.6 million at the end of fiscal year 2010. Working capital was $111.1 million, compared to $88.5 million as of June 30, 2010. Shareholders' equity was $157.7 million, as compared to $134.5 million at the end of fiscal year 2010.
The Company generated $13.6 million in cash flow from operating activities during the three months ended September 30, 2010. Net cash flow used in investing activities was $0.2 million.
Due to restrictions on the Company's ability to transfer cash out of the PRC, the Company has been delinquent in the payment of interest on its November 2007 Debentures and May 2008 Notes. Management has been in close discussions with holders of the November 2007 Debentures and May 2008 Notes in order to reach a resolution to this issue in the near-term.
Recent Development
The Company completed the renovation of its Hongrui factory in October 2010 and passed the examination by Shandong Food and Drug Administration. The Company has applied for the license of Good Manufacturing Practice ("GMP"). The Company expects to receive the GMP license by December 2010 and plans to plans to re-launch several of the traditional Chinese medicines it acquired in the February 2009 Hongrui acquisition immediately upon receipt of the GMP license.
Business Outlook and Guidance
While Clarithromycin sustained-release tablets, Itopride Hydrochloride granules and Baobaole chewable tablets have reached mature stages in their product lifecycles, the Company believes that its total current sales levels can be maintained in fiscal year 2011.
Management continues to estimate that the portfolio of TCM drugs to be manufactured at Hongrui will generate revenues of $7 million to $15 million during the first year of production, beginning in the second quarter of fiscal year 2011. Felodipine is expected to generate revenues of $8 million to $12 million during the first twelve months after its launch, which took place this quarter.
Therefore, based on its current outlook, the Company reaffirms guidance for fiscal year 2011 of revenues between $94 million and $96 million and net income, excluding the impact from change in fair value of derivative liabilities and expenses related to the Company's convertible debentures, between $29 million and $31 million.
"We ended the quarter with over $123 million in cash and are evaluating ways to deploy our capital to enhance the growth and profitability of our product portfolio and improve our strategic positioning within China's rapidly growing pharmaceutical industry. In particular, we are targeting strategic acquisitions that will strengthen our market position and vertically integrate our operations," concluded Mr. Jin.
Conference Call
The management of Jiangbo Pharmaceuticals, Inc. will host a conference call at 10:00 a.m. Eastern Standard Time on Tuesday, November 16, 2010 to discuss financial results for the first quarter fiscal 2011 ended September 30, 2010. The conference call will be hosted by Mr. Linxian Jin, CEO, and Ms. Elsa Sung, CFO, of Jiangbo. To participate in the live conference call, please dial the following number five to ten minutes prior to the scheduled conference call time: (800) 815-0215. International callers should dial (706) 758-5465. The Conference ID for this call is 24282922. If you are unable to participate on the live call, a replay will be available for 14 days starting on Tuesday, November 16, 2010 at 11:00 a.m. Eastern Standard Time. To access the replay, dial (800) 642-1687, international callers dial (706) 645-9291. The Conference ID is 24282922.
Use of Non-GAAP Financial Information
This press release includes certain financial information, adjusted net income and adjusted fully diluted earnings per share, which are not presented in accordance with GAAP. Adjusted net income was derived by taking net income and adjusting it with a loss from discontinued operations, unrealized losses on trading securities and non-cash amortization of debt discount and debt issuance costs related to convertible securities. The Company's management believes that these non-GAAP measures provide investors with a better understanding of the Company's historical results from its core business operations. To supplement the Company's condensed consolidated financial statements presented on a GAAP basis, the Company has provided non-GAAP financial information, which is adjusted net income and adjusted earnings per share, excluding the impact of these items in this release. The non-GAAP information is not meant to be considered in isolation or as a substitute for GAAP financials. The non-GAAP financial information provided by the Company may also differ from non-GAAP information provided by other companies. A table below provides a reconciliation of the non-GAAP financial information to the nearest GAAP measure.
About Jiangbo Pharmaceuticals, Inc.
Jiangbo Pharmaceuticals is engaged in the research, development, production, marketing and sales of pharmaceutical products in China. The Company's operations are located in Eastern China in an Economic Development Zone in Laiyang City, Shandong Province. Jiangbo produces both western and Chinese herbal-based medical drugs in tablet, capsule, granule, syrup and electuary (sticky syrup) form. For additional information, please visit the Company's website (http://www.jiangbopharma.com/).
Safe Harbor Statement
ich nicht mehr. Ist wie bei Morphosys.
Optionen
| Boardmail an "wanderbroker" |
Wertpapier: JIANGBO PHARMACEUTICALS |
Das grosse Problem liegt darin,das die Firma bisher keine Möglichkeit gefunden hat die
fälligen Zinsen in US-Dollar zu zahlen.
Es liest sich nicht gut,Anleger sind solange vorsichtig.
Due to restrictions on the Company's ability to transfer cash out of the PRC, the Company has been delinquent in the payment of interest on its November 2007 Debentures and May 2008 Notes. Management has been in close discussions with holders of the November 2007 Debentures and May 2008 Notes in order to reach a resolution to this issue in the near-term.
Das Misstrauen in den USA zu Chinaaktien ,welche in den USA gelistet sind steigt.
Es wird bei yahoo kräftig gebasht,allerdings machen sie es nicht aus Spass oder
Nächstenliebe.
Bei rino ist wohl einige schief gelaufen.
Nun kommen andere Firmen,die auch von bei frazer frost betreut werden mit in den Strudel.
Wo liegt die nächste Unterstützung?
Danke im vorraus